| Drug General Information |
| Drug ID |
D01JYY
|
| Former ID |
DNC010176
|
| Drug Name |
(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H24N2O
|
| Canonical SMILES |
CC(C)CN(C1CCNC1)C(=O)C2=CC3=CC=CC=C3C=C2
|
| InChI |
1S/C19H24N2O/c1-14(2)13-21(18-9-10-20-12-18)19(22)17-8-7-15-5-3-4-6-16(15)11-17/h3-8,11,14,18,20H,9-10,12-13H2,1-2H3/t18-/m1/s1
|
| InChIKey |
CEUJKSVEPJAVKD-GOSISDBHSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Sodium-dependent serotonin transporter |
Target Info |
Inhibitor |
[1]
|
|---|
| Potassium voltage-gated channel subfamily H member 2 |
Target Info |
Inhibitor |
[1]
|
| Sodium-dependent dopamine transporter |
Target Info |
Inhibitor |
[1]
|
| Sodium-dependent noradrenaline transporter |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Serotonergic synapsehsa04728:Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Alcoholism
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
5HT1 type receptor mediated signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
5HT3 type receptor mediated signaling pathway
|
|
5HT4 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
|
Parkinson disease
|
|
Dopamine receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
|
Pathway Interaction Database
|
Alpha-synuclein signaling
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
Voltage gated Potassium channelsR-HSA-442660:Na+/Cl- dependent neurotransmitter transportersR-HSA-442660:Na+/Cl- dependent neurotransmitter transporters
|
|
WikiPathways
|
Monoamine Transport
|
|
SIDS Susceptibility Pathways
|
|
NRF2 pathway
|
|
Synaptic Vesicle Pathway
|
|
Serotonin Transporter ActivityWP706:SIDS Susceptibility Pathways
|
|
Hematopoietic Stem Cell Differentiation
|
|
Potassium ChannelsWP727:Monoamine Transport
|
|
Dopaminergic Neurogenesis
|
|
Parkinsons Disease Pathway
|
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
|
|
Neurotransmitter Clearance In The Synaptic CleftWP727:Monoamine Transport
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. |
|---|
